Merck Expands Portfolio with Key FDA Approvals and R&D Investments
Merck (MRK) is making significant strides across multiple therapeutic areas, with recent FDA approvals and clinical trial progress highlighting its commitment to broadening its revenue drivers. The company secured FDA approval for the WELIREG plus LENVIMA combination in advanced renal cell carcinoma, an updated label for WINREVAIR in pulmonary arterial hypertension, and promising Phase 2b/3 BRUNELLO data in diabetic macular edema. These developments, along with licensing deals and collaboration progress, demonstrate Merck's strategy to diversify its portfolio beyond its flagship product, KEYTRUDA.
The investment narrative around Merck centers on its heavy spending to refresh its drug portfolio ahead of KEYTRUDA facing cheaper rivals. The near-term focus is on how quickly newer products and late-stage trials can translate into steady prescription demand. While recent updates reinforce Merck's R&D-heavy story, risks remain, including clinical and safety uncertainties seen with remigromig’s adverse event profile and the withdrawal of ifinatamab deruxtecan.
Merck's pipeline also includes the SciBrunch deal for SPR2015, a KRAS G12D inhibitor, which involves a US$400 million pre-tax charge in Q3 2026 and up to US$2.13 billion in potential payments tied to development, regulatory, and sales milestones. This deal is part of Merck's push to build more than 20 future growth drivers, but it also introduces additional risks. The company projects US$75.3 billion in revenue and US$22.5 billion in earnings by 2029, assuming 4.2% yearly revenue growth and a US$19.3 billion increase in earnings from US$3.2 billion today.
Analysts offer varying perspectives on Merck's future. Optimistic projections suggest a 10% potential upside to the current price, while more cautious analysts set price targets near US$105, warning that newer drugs may not offset KEYTRUDA concentration. The recent WELIREG plus LENVIMA approval could reshape these expectations over time, making it essential for investors to compare different narratives and decide which assumptions align with their views.